TW200500070A - Method of improved diuresis in individuals with impaired renal function - Google Patents
Method of improved diuresis in individuals with impaired renal functionInfo
- Publication number
- TW200500070A TW200500070A TW093111522A TW93111522A TW200500070A TW 200500070 A TW200500070 A TW 200500070A TW 093111522 A TW093111522 A TW 093111522A TW 93111522 A TW93111522 A TW 93111522A TW 200500070 A TW200500070 A TW 200500070A
- Authority
- TW
- Taiwan
- Prior art keywords
- individuals
- renal function
- impaired renal
- diuresis
- improved
- Prior art date
Links
- 208000004880 Polyuria Diseases 0.000 title abstract 3
- 206010062237 Renal impairment Diseases 0.000 title 1
- 230000035619 diuresis Effects 0.000 title 1
- 231100000857 poor renal function Toxicity 0.000 title 1
- 230000001882 diuretic effect Effects 0.000 abstract 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46600703P | 2003-04-25 | 2003-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200500070A true TW200500070A (en) | 2005-01-01 |
Family
ID=33418325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093111522A TW200500070A (en) | 2003-04-25 | 2004-04-23 | Method of improved diuresis in individuals with impaired renal function |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7579331B2 (https=) |
| EP (1) | EP1620107A1 (https=) |
| JP (1) | JP2006524699A (https=) |
| KR (1) | KR20060004959A (https=) |
| CN (1) | CN1859913A (https=) |
| AR (1) | AR044069A1 (https=) |
| AU (1) | AU2004233852A1 (https=) |
| BR (1) | BRPI0409699A (https=) |
| CA (1) | CA2522971A1 (https=) |
| MX (1) | MXPA05011371A (https=) |
| NO (1) | NO20055536L (https=) |
| NZ (1) | NZ543109A (https=) |
| RU (1) | RU2367442C2 (https=) |
| TW (1) | TW200500070A (https=) |
| WO (1) | WO2004096228A1 (https=) |
| ZA (1) | ZA200509311B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| MXPA05011371A (es) | 2003-04-25 | 2005-12-01 | Novacardia Inc | Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada. |
| US20060293312A1 (en) * | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
| CA2536975A1 (en) * | 2003-08-28 | 2005-03-17 | Nitromed, Inc. | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use |
| BRPI0509753A (pt) * | 2004-04-16 | 2007-10-16 | Novacardia Inc | composição farmacêutica e método de tratamento de doença cardiovascular |
| WO2006091716A2 (en) * | 2005-02-24 | 2006-08-31 | Nitromed, Inc. | Nitric oxide enhancing diuretic compounds, compositions and methods of use |
| EP1928414A2 (en) * | 2005-04-22 | 2008-06-11 | Novacardia, Inc. | Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions |
| JPWO2007069675A1 (ja) * | 2005-12-14 | 2009-05-28 | 協和発酵キリン株式会社 | キサンチン誘導体の易吸収性経口製剤 |
| AU2007235372A1 (en) * | 2006-04-06 | 2007-10-18 | Novacardia, Inc. | Co-administration of adenosine A1 receptor antagonists and anticonvulsants |
| EP2035092A2 (en) * | 2006-06-16 | 2009-03-18 | Novacardia, Inc. | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload |
| CN101466383A (zh) * | 2006-06-16 | 2009-06-24 | 美国诺华卡迪亚公司 | 包含低频率投与aa1ra的肾功能延长改善 |
| WO2008121882A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Improved methods of administration of adenosine a1 receptor antagonists |
| US20090197900A1 (en) * | 2007-03-29 | 2009-08-06 | Howard Dittrich | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416810C (sv) | 1977-10-14 | 1982-07-19 | Draco Ab | Forfarande for framstellning av xantinderivat med antiallergisk aktivitet |
| FR2531085A1 (fr) | 1982-07-28 | 1984-02-03 | Adir | Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| US4769377A (en) | 1983-02-18 | 1988-09-06 | The Johns Hopkins University | Adenosine receptor antagonists |
| DE8817122U1 (de) | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| US5290782A (en) | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| SE9000207L (sv) | 1990-01-22 | 1991-07-23 | Nobel Chemicals Ab | Laekemedel samt anvaendningen av detsamma |
| DE4019892A1 (de) | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| AU2297192A (en) | 1991-06-28 | 1993-01-25 | Sepracor, Inc. | Optically pure s(-) nadolol for treatment of cardiovascular disorders |
| CA2093403C (en) | 1992-04-08 | 1999-08-10 | Fumio Suzuki | Therapeutic agent for parkinson's disease |
| TW252044B (https=) | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
| DE4238367A1 (de) | 1992-11-13 | 1994-05-19 | Boehringer Ingelheim Kg | Diuretisches Mittel |
| US5395836A (en) | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
| US5446046A (en) | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
| US5736528A (en) | 1993-10-28 | 1998-04-07 | University Of Florida Research Foundation, Inc. | N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists |
| CN1049117C (zh) | 1994-09-16 | 2000-02-09 | 赵明玉 | 预防和治疗偏头痛的偏头痛片 |
| US6254889B1 (en) | 1995-07-26 | 2001-07-03 | Kyowa Hakko Kogyo Co., Ltd. | Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer |
| ATE281835T1 (de) | 1996-08-07 | 2004-11-15 | Kyowa Hakko Kogyo Kk | Fettemulsion, die ein xanthinderivat enthält |
| DE19816857A1 (de) | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US6187780B1 (en) | 1998-04-16 | 2001-02-13 | Boehringer Ingelheim Pharma Kg | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity |
| ATE252905T1 (de) | 1998-04-24 | 2003-11-15 | Biogen Inc | Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion |
| US20020115687A1 (en) | 1998-04-24 | 2002-08-22 | Evan Beckman | Method and composition for restoring diuretic and renal function |
| EP0970696A1 (en) | 1998-05-05 | 2000-01-12 | Kyowa Hakko Kogyo Co., Ltd. | Combination of loop diuretics with adenosine A1-receptor antagonists |
| UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| CN100390178C (zh) | 1999-11-12 | 2008-05-28 | 拜奥根Idec马萨诸塞公司 | 作为腺苷受体拮抗剂的多环烷基嘌呤 |
| MXPA02004795A (es) | 1999-11-12 | 2005-07-01 | Biogen Inc | Antagonistas del receptor de adenosina y los metodos para producir y utilizar los mismos. |
| US20050038017A1 (en) | 1999-12-22 | 2005-02-17 | Wolff Andrew A. | Method and composition for restoring diuretic and renal function |
| BR0115833A (pt) | 2000-12-01 | 2003-10-28 | Biogen Inc | Derivados condensados de purina como antagonistas de receptores de adenosina a1 |
| HUP0302455A3 (en) | 2000-12-18 | 2005-05-30 | Novartis Ag | Combination pharmaceutical compositions containing amplodipine and benazepril and their use |
| UA80258C2 (en) | 2001-09-06 | 2007-09-10 | Biogen Inc | Methods of treating pulmonary disease |
| US20040229901A1 (en) | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| MXPA05011371A (es) | 2003-04-25 | 2005-12-01 | Novacardia Inc | Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada. |
| US20060293312A1 (en) | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
| US20050070524A1 (en) | 2003-06-06 | 2005-03-31 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
| BRPI0509753A (pt) | 2004-04-16 | 2007-10-16 | Novacardia Inc | composição farmacêutica e método de tratamento de doença cardiovascular |
| CA2565037A1 (en) | 2004-04-28 | 2005-11-10 | Cv Therapeutics, Inc. | Purine derivatives as a1 adenosine receptor antagonists |
| AU2007235372A1 (en) | 2006-04-06 | 2007-10-18 | Novacardia, Inc. | Co-administration of adenosine A1 receptor antagonists and anticonvulsants |
| CN101466383A (zh) | 2006-06-16 | 2009-06-24 | 美国诺华卡迪亚公司 | 包含低频率投与aa1ra的肾功能延长改善 |
| EP2035092A2 (en) | 2006-06-16 | 2009-03-18 | Novacardia, Inc. | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload |
| EP2061793A2 (en) | 2006-08-22 | 2009-05-27 | Novacardia, Inc. | Kw-3902 conjugates that do not cross the blood-brain barrier |
-
2004
- 2004-04-23 MX MXPA05011371A patent/MXPA05011371A/es not_active Application Discontinuation
- 2004-04-23 CN CNA2004800105597A patent/CN1859913A/zh active Pending
- 2004-04-23 US US10/830,617 patent/US7579331B2/en not_active Expired - Fee Related
- 2004-04-23 JP JP2006513242A patent/JP2006524699A/ja not_active Withdrawn
- 2004-04-23 RU RU2005131938/15A patent/RU2367442C2/ru not_active IP Right Cessation
- 2004-04-23 AU AU2004233852A patent/AU2004233852A1/en not_active Abandoned
- 2004-04-23 BR BRPI0409699-1A patent/BRPI0409699A/pt not_active IP Right Cessation
- 2004-04-23 EP EP04760339A patent/EP1620107A1/en not_active Withdrawn
- 2004-04-23 TW TW093111522A patent/TW200500070A/zh unknown
- 2004-04-23 KR KR1020057020243A patent/KR20060004959A/ko not_active Ceased
- 2004-04-23 CA CA002522971A patent/CA2522971A1/en not_active Abandoned
- 2004-04-23 NZ NZ543109A patent/NZ543109A/en unknown
- 2004-04-23 WO PCT/US2004/012518 patent/WO2004096228A1/en not_active Ceased
- 2004-04-23 AR ARP040101381A patent/AR044069A1/es unknown
-
2005
- 2005-10-11 US US11/248,479 patent/US20060030572A1/en not_active Abandoned
- 2005-10-11 US US11/248,905 patent/US20060035911A1/en not_active Abandoned
- 2005-11-17 ZA ZA200509311A patent/ZA200509311B/en unknown
- 2005-11-23 NO NO20055536A patent/NO20055536L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20055536D0 (no) | 2005-11-23 |
| MXPA05011371A (es) | 2005-12-01 |
| RU2005131938A (ru) | 2006-06-27 |
| AR044069A1 (es) | 2005-08-24 |
| KR20060004959A (ko) | 2006-01-16 |
| EP1620107A1 (en) | 2006-02-01 |
| CA2522971A1 (en) | 2004-11-11 |
| NZ543109A (en) | 2008-06-30 |
| US20060035911A1 (en) | 2006-02-16 |
| US20060030572A1 (en) | 2006-02-09 |
| RU2367442C2 (ru) | 2009-09-20 |
| US20050004145A1 (en) | 2005-01-06 |
| ZA200509311B (en) | 2006-10-25 |
| BRPI0409699A (pt) | 2006-04-18 |
| CN1859913A (zh) | 2006-11-08 |
| WO2004096228A1 (en) | 2004-11-11 |
| US7579331B2 (en) | 2009-08-25 |
| JP2006524699A (ja) | 2006-11-02 |
| AU2004233852A1 (en) | 2004-11-11 |
| NO20055536L (no) | 2005-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007149285A3 (en) | Method of improved diuresis in individuals with impaired renal function | |
| TW200500070A (en) | Method of improved diuresis in individuals with impaired renal function | |
| WO2003026591A3 (en) | Modification of feeding behavior | |
| DK1416842T3 (da) | Farmaceutiske kombinationer af oxycodon og naloxon | |
| EP1513825A4 (en) | ANTITU-CULINARY MEDICAMENT: COMPOSITIONS AND METHODS | |
| ATE374016T1 (de) | Tablette mit hohem wirkstoffgehalt | |
| DK1663229T3 (da) | Farmaceutiske kombinationer af hydrocodon og naltrexon | |
| ATE431738T1 (de) | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist | |
| AU2003243551A1 (en) | Use of an anti-endotoxin drug in the prevention and treatment of disease | |
| EP1711207A4 (en) | INTERFERON ALPHA ANTIBODIES AND ITS USES | |
| WO2004000354A3 (en) | Method of treating the syndrome of lipodystrophy | |
| AR042534A1 (es) | Formas de dosificacion que comprenden un inhibidor de la proteina de transferencia de esteres de colesterilo (ptec) y un inhibidor de la 3-hidroxi-3-metil glutaril-coenzima a (hmg-co-a) reductasa | |
| MA27233A1 (fr) | Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique | |
| PL371523A1 (en) | Method of treatment of a patient requiring analgesia | |
| NO20051658L (no) | Terapeutisk behandling | |
| AU2003238242A1 (en) | Use of an anti-endotoxin drug in the prevention and treatment of disease | |
| MY133169A (en) | Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect | |
| CY1109215T1 (el) | Συστημα χορηγησης οπιοειδους | |
| FR2873693B1 (fr) | Derives d'amino-tropane, leur preparation et leur application en therapeutique | |
| AU2003211630A1 (en) | Cigarette reduced in the amount of sub-stream smoke | |
| NO20051261L (no) | Morfin-6-glukuronidsalt | |
| AU2003248893A1 (en) | Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias | |
| FR2842527B1 (fr) | Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique | |
| AU2003240052A1 (en) | Il-11 derivatives and therapeutic uses thereof | |
| AU2003221289A1 (en) | An artificial low toxicity tobacco base and a method using the tobacco base |